Firebrick Pharma (ASX:FRE) Announces Manufacturing of New Nasodine Throat Spray

In a key investor update, Firebrick Pharma Limited (ASX:FRE) has announced the commencement of manufacturing for its second product in the Nasodine range: the Nasodine Throat Spray. This development is the first new Nasodine product since the nasal spray launch in Singapore, positioning the company for revenue generation through export markets beginning in November 2025.

The biotechnology company has secured TGA export permits and partnered with Australian manufacturer Probiotec for initial production, with the first batch expected to be available for export in November 2025. The Firebrick Pharma Nasodine Throat Spray launch represents a planned expansion of the company’s povidone-iodine product portfolio, targeting the global sore throat treatment market through an innovative spray format that removes the inconvenience of traditional gargle solutions. This ASX announcement details the commercialisation timeline and market entry plan.

What Sets Firebrick Pharma’s Throat Spray Apart from Traditional Treatments?

Nasodine Throat Spray is a 1.0% povidone-iodine antiseptic formulation designed for sore throat treatment. The product delivers targeted therapy through an innovative spray mechanism that differentiates it from traditional throat gargle solutions available in most markets.

The 25mL bottles feature an integrated precision nozzle that provides direct application to affected throat areas without requiring expectoration. This eliminates the mess and inconvenience associated with traditional gargle formats whilst preventing potential staining from unused solution—a common complaint amongst users of conventional throat gargle products.

Povidone-iodine is a broad-spectrum antiseptic that effectively eliminates bacteria, viruses, and fungi on contact. For healthcare investors, this established active ingredient offers decades of clinical validation and regulatory acceptance across international markets, reducing development risks whilst providing proven therapeutic efficacy.

The formulation’s pleasant taste addresses another common barrier to patient compliance with antiseptic throat treatments, potentially improving adherence rates and therapeutic outcomes compared to alternatives with less palatable profiles.

When is the Nasodine Throat Spray Launch Scheduled to Generate Revenue?

Firebrick has established a clear commercialisation timeline with multiple phases of market entry planned across 2025 and 2026. The company expects to begin generating export revenue as early as November 2025, following completion of initial production runs with manufacturing partner Probiotec at their Australian facility.

The Singapore market entry plan leverages the product’s classification as an antiseptic, requiring no local regulatory approval. This regulatory advantage, combined with Firebrick’s established presence through the Nasodine Nasal Spray, positions the company for rapid market penetration and accelerated revenue generation.

Furthermore, distribution partner Innorini Life Sciences will focus initially on healthcare professional channels, targeting Singapore hospitals and medical practitioners before expanding to consumer retail channels in mid-2026. This phased approach allows for clinical validation and professional endorsement before mass-market availability.

The TGA export permit (registration number 517465) enables immediate international sales whilst maintaining Australian manufacturing standards, creating flexibility for additional market expansion beyond Singapore as commercial momentum builds.

How Does This Product Launch Impact Firebrick Pharma’s Investment Profile?

The Firebrick Pharma Nasodine Throat Spray launch represents a key revenue diversification event for the company, demonstrating its ability to leverage core povidone-iodine expertise across multiple product formats. This expansion reduces single-product dependency whilst creating multiple revenue streams from established markets.

With a market capitalisation of approximately $16.1 million, shares on issue of around 231 million, and cash reserves of $1.938 million as of October 2025, the company’s ability to bring additional products to market without raising new capital demonstrates efficient resource allocation.

Investment Advantages:

The product launch validates Firebrick’s scalable manufacturing model through its partnership with Probiotec, an established Australian pharmaceutical manufacturer. This approach minimises capital expenditure requirements whilst ensuring quality control and regulatory compliance, preserving cash for product development and commercial expansion.

The throat spray format is already available in Singapore under competing brands, but is not currently available in Australia. This indicates both proven market demand and a competitive opportunity for Firebrick’s entry, particularly given the company’s existing brand recognition from its nasal spray product.

In addition, the company’s announcement states that additional Nasodine-brand products will follow, suggesting a broad product portfolio plan that could expand the investment thesis beyond this single product launch.

What is the Revenue Potential of the Nasodine Throat Spray?

The throat spray launch creates immediate and long-term revenue opportunities across multiple market segments and geographic regions. Beginning with export revenue in November 2025, the product offers scalable commercial potential through Firebrick’s established distribution networks across four international markets.

Revenue Generation Framework:

The healthcare professional channel provides the initial revenue foundation, targeting Singapore’s medical sector through Innorini’s established relationships. This B2B approach typically offers higher margins and more predictable ordering patterns compared to consumer retail channels, whilst simultaneously building clinical credibility for subsequent retail expansion.

Consumer retail expansion planned for mid-2026 represents the larger long-term opportunity, with over-the-counter availability through Singapore’s established pharmacy and retail networks. The reported success of Nasodine Nasal Spray in consumer channels provides a strong precedent for market acceptance.

Geographic Expansion Potential:

Firebrick’s existing presence in the United States, Singapore, Fiji, and Brunei creates multiple expansion pathways for the throat spray format beyond the initial Singapore launch. Each market represents an established distribution relationship that could accommodate additional product introductions with minimal incremental investment.

The company’s focus on antiseptic classifications may enable rapid market entry without lengthy regulatory approval processes in many jurisdictions. This regulatory advantage accelerates time-to-revenue whilst reducing commercialisation costs compared to products requiring full pharmaceutical approval pathways.

Moreover, the throat treatment market represents a large addressable opportunity, with sore throats being among the most common reasons for medical consultations and over-the-counter remedy purchases globally. This market size enhances the revenue potential of the throat spray relative to Firebrick’s existing nasal spray product.

How Does the Manufacturing Partnership Support Firebrick Pharma’s Growth?

Firebrick’s collaboration with Probiotec for manufacturing represents a capital-efficient approach to product commercialisation. Probiotec is an established Australian pharmaceutical manufacturer with experience in topical antiseptic formulations, providing both production capacity and regulatory expertise.

This partnership model allows Firebrick to maintain focus on product development and commercial plans whilst leveraging external manufacturing expertise. For investors, this approach reduces fixed overhead costs and capital investment requirements compared to building proprietary manufacturing infrastructure.

The manufacturing timeline—with product release expected during November 2025—demonstrates rapid execution from announcement to market availability, indicating established manufacturing processes and regulatory pathways. This execution speed provides confidence in the company’s ability to deliver on commercial milestones.

What is the Role of Singapore in Firebrick Pharma’s Commercial Plan?

Singapore represents a key beachhead market for Firebrick’s Nasodine product range, offering several distinct advantages for commercialisation. The city-state’s classification of povidone-iodine products as antiseptics rather than pharmaceuticals eliminates certain regulatory approval requirements, enabling more rapid market entry.

Furthermore, the market’s sophisticated healthcare infrastructure and high per-capita healthcare spending create an attractive commercial environment for premium healthcare products. This allows Firebrick to establish a strong market presence before expanding into other regions, setting a foundation for the global rollout of the Nasodine Throat Spray.

Want more ASX news?

Looking to stay informed on significant ASX biotechnology announcements like Firebrick Pharma’s recent product launch? Join over 20,000 investors who receive StockWire X’s Big News Blasts—a free email service delivering major company announcements from non-resource ASX companies directly to subscribers’ inboxes, complete with comprehensive analysis. This quality-filtered service ensures investors receive only the most important market-moving news across biotechnology, technology, healthcare, finance, and industrials sectors. Subscribe to Big News Blasts today for instant alerts on the announcements that matter most.